Biotinylated Human PD-L2/B7-DC Protein
Catalog No: PDL2-HB003
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human PD-L2/B7-DC Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Leu20-Thr220 (UniProt accession: Q9BQ51-1).
Product Details
- Molecular Aliases
- PDL2; PD-L2; Butyrophilin B7-DC; CD273, PDCD1 ligand 2; PDCD1L2; PDCD1LG2; B7DC; bA574F11.2; Btdc; Butyrophilin B7DC
- Protein Length
- Leu20-Thr220
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 25.3 kDa. Due to glycosylation, the protein migrates to 40-52 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human PD-L2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human PD-L2 is greater than 90% as determined by SEC-HPLC.
Human PD-1, hFc Tag captured on CM5 Chip via Protein A can bind Biotinylated Human PD-L2, His-Avi tag with an affinity constant of 0.344 μM as determined in SPR assay (Biacore T200). (QC Test)
Background
PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4 T cells. At low antigen concentrations, PD-L2-PD-1 interactions inhibit strong B7-CD28 signals.
References
- Yearley JH, Gibson C, Yu N, et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017;23(12):3158-3167. doi:10.1158/1078-0432. CCR-16-1761
Have questions about this product?
Our technical team can help with product selection, application questions and order support.